By late 2025, the global nasal spray market has consolidated significantly, with the top two manufacturers alone controlling approximately 27% of the total market share. GlaxoSmithKline (GSK) remains the global leader with a 15% share, driven by its robust portfolio of 12 branded products, including Avamys and Veramyst. GSK's focus in 2025 has shifted toward "circular economy" initiatives, replacing traditional propellants with eco-conscious alternatives to meet European sustainability mandates.

Cipla Inc. has emerged as the second-largest global player with a 12% share. The company has aggressively expanded its footprint, launching 11 new products since 2023. A key driver for Cipla in 2025 is its strategic positioning in the "Epinephrine Nasal Spray" segment (Neffy), following its inclusion in the FDA's March 2025 Orange Book. For a detailed breakdown of the revenue generated by other major players like Sanofi, Bayer, and Viatris, refer to the Nasal Spray Market competitive analysis.